How much startup capital is defintely required for this business?

Based on the financial model, you need to secure enough funding to cover the $375,000 in initial capital expenditures and the minimum cash requirement of $805,000, which is projected for February 2026 This high upfront need covers specialized equipment and regulatory compliance costs

What is the projected timeline for reaching profitability?

The model shows a rapid path to profitability, with the business reaching cash flow breakeven in just 2 months (February 2026) and achieving a full payback period within 11 months, driven by strong unit economics and high ASPs

What are the primary revenue drivers in the 5-year forecast?

Revenue growth is driven by the VenaFlow Home System, scaling from 800 units in 2026 to 14,000 units in 2030, plus the high-volume Disposable Garment Packs, which jump from 12,000 to 380,000 units in the same period

What percentage of revenue is absorbed by Cost of Goods Sold?

Your initial COGS is projected at 110% of revenue in 2026 (85% manufacturing, 25% packaging) This low cost structure is key to achieving a high Return on Equity (ROE) of 7939% by the end of the forecast

Sequential Compression Device Sales Plan: 7 Steps, 5-Year Forecast

How to Write a Business Plan for Sequential Compression Device Sales

Follow 7 practical steps to create a Sequential Compression Device Sales business plan in 10-15 pages, with a 5-year forecast and breakeven reached quickly in 2 months

How to Write a Business Plan for Sequential Compression Device Sales in 7 Steps

#	Step Name	Plan Section	Key Focus	Main Output/Deliverable
1	Define Product Portfolio and Regulatory Status	Concept	Confirm FDA clearance for VenaFlow Pro ($2,450 ASP) and Home ($850 ASP); model recurring revenue from $45 Garment Packs.	Clear product specs and revenue streams.
2	Analyze Target Market and Pricing Strategy	Market	Justify 2026 unit sales (450 Pro, 800 Home) based on penetration of hospital and orthopedic groups.	Validated 2026 unit sales forecast.
3	Structure COGS and Supply Chain	Operations	Lock down contract manufacturing costs (85% of 2026 revenue) and plan logistics for scaling disposables from 12,000 to 380,000 units by 2030.	Documented inventory management plan.
4	Build the Core Team and Salary Model	Team	Detail the 7 FTE starting team (CEO $185k, Quality Dir $145k) and map hiring to reach 31 FTEs by 2030.	2030 headcount and salary structure.
5	Calculate Startup Costs and Funding Needs	Financials	Total CapEx ($375k, including $125k molds) and pinpoint the $805,000 minimum cash requirement in February 2026.	Final minimum cash requirement figure.
6	Develop the 5-Year Profit and Loss (P&L) Forecast	Financials	Project revenue scaling from $23 million in 2026 to $488 million in 2030, confirming high IRR (2442%) and ROE (7939%).	Full 5-year projected P&L.
7	Determine Breakeven and Profitability Levers	Risks	Confirm rapid breakeven (2 months, Feb 2026) but stress that managing the 110% Cost of Goods Sold is the main margin lever.	Confirmed breakeven timeline and margin focus.

Who are the primary decision-makers and payors for Sequential Compression Device Sales?

The decision-makers for Sequential Compression Device Sales depend entirely on the sales channel chosen: hospitals and surgical centers (B2B procurement) or individual patients via physician prescription (DTC). This choice directly controls the sales cycle length and the regulatory path you must follow; understanding these initial hurdles is key, which is why you should review How Much To Start Sequential Compression Device Sales Business?

Institutional Buyers (B2B)

Procurement teams at hospitals and rehabilitation facilities hold the final purchasing authority.
Sales cycles are long, often requiring 6 to 12 months to close a major facility contract.
You must satisfy clinical requirements from department heads and navigate GPO (Group Purchasing Organization) compliance.
The pitch centers on long-term cost reduction and proven clinical outcomes for DVT prevention.

Patient & Provider Sales (DTC)

The physician acts as the gatekeeper by writing the necessary prescription.
Payors are typically Medicare/Medicaid or private insurance, processed through a Durable Medical Equipment (DME) provider partner.
If patient onboarding takes 14+ days, churn risk rises; speed is defintely critical here.
Revenue relies on securing and maintaining accurate HCPCS codes for billing compliance.

How will we maintain FDA compliance and quality management systems (QMS) as we scale?

You're looking at a fixed compliance bill of $7,700 monthly for Sequential Compression Device Sales, which means your baseline operating expense before hiring regulatory staff is $92,400 annually. This cost structure must be baked into your margin analysis now, especially if you want to know How Increase Sequential Compression Device Sales Profits?.

Fixed Compliance Burden

Fixed regulatory costs stand at $3,200/month.
QMS maintenance requires another $4,500/month.
That's $92,400 in overhead before any compliance salaries.
These are non-negotiable costs for FDA clearance maintenance.

Scaling Compliance Headroom

If you sell 100 units, compliance cost per unit is $77.
Staffing costs are an additional variable layer on top.
You need to ensure your Average Order Value (AOV) covers this floor.
If onboarding takes longer than expected, these fixed costs burn cash fast.

What is the true blended contribution margin, considering both high-value systems and low-value disposables?

The true blended contribution margin for Sequential Compression Device Sales hinges entirely on shifting sales mix toward the $2,450 VenaFlow Pro System, as the low-value $45 disposables alone won't generate the required profitability to support the 5-year $365 million EBITDA goal. Understanding the underlying expenses is crucial; you can review the details on What Are Operating Costs For Sequential Compression Device Sales?, but the core issue is balancing the high ASP against the stated 200% total variable cost structure.

System Profit Drivers

System ASP is $2,450; this unit carries the fixed overhead.
Focus sales efforts on clinical centers first.
High-value sales build the base for margin expansion.
If variable costs are managed near 50%, contribution is strong.

Disposable Margin Drag

Garment Packs sell for only $45 per unit.
These consumables dilute the blended rate quickly.
If the 200% variable cost structure applies here, these units lose money.
Growth must prioritize system volume over disposable attachment rate initially.

What is the scalable sales strategy to move from 2 to 15 Medical Sales Representatives (FTEs) by 2030?

Scaling Sequential Compression Device Sales from 2 to 15 sales representatives by 2030 requires a disciplined territory map, a heavily incentive-based commission plan, and rigorous training to support the jump from 800 to 14,000 units sold.

Territory Planning for Unit Growth

Divide the US market into 15 distinct territories based on procedure volume.
Targeting 14,000 units means each rep must sell about 933 units annually.
Initial hires should focus on regions with established relationships in orthopedic surgery.
Define clear performance metrics for territory penetration, not just raw sales numbers.

Compensation and Rep Enablement

Structure Year 1 compensation so 60% of revenue is paid out via commission to drive immediate unit sales.
Reps need intensive training on clinical application and reimbursement codes; this is defintely non-negotiable.
Tie residual commission structures to patient adherence data to ensure long-term device utilization.
Understand the full revenue picture when setting targets; review how much owners make from sales, like in the How Much Does An Owner Make From Sequential Compression Device Sales? analysis.

Key Takeaways

The business plan anticipates an exceptionally rapid financial turnaround, reaching cash flow breakeven within just 2 months of launching in February 2026.
Initial funding requirements are substantial, demanding $375,000 for capital expenditures alongside a minimum operational cash reserve of $805,000.
The strategic focus on scalable disposable revenue supports aggressive sales expansion, projecting revenue to hit $171 million by Year 3 and $488 million by Year 5.
High profitability is driven by the blended margin structure, leading to a projected 5-year EBITDA of $365 million and an impressive Return on Equity (ROE) of 7939%.

Step 1 : Define Product Portfolio and Regulatory Status

Product Line & Clearance

You need clear product definitions defintely before forecasting sales. We have two main capital units: the VenaFlow Pro System at a $2,450 ASP (Average Selling Price) and the VenaFlow Home System at $850 ASP. Both devices carry necessary FDA clearance, which validates their safety for medical use. This regulatory hurdle is cleared, letting us focus on market entry.

Consumable Revenue Stream

The real value driver is consumables, not just the initial hardware sale. Patients require Disposable Garment Packs for therapy, priced at $45 ASP. This creates a sticky customer base. If we sell 450 Pro Systems in 2026, that's 450 recurring customers needing these packs right away. That recurring spend is key to long-term valuation.

Step 2 : Analyze Target Market and Pricing Strategy

Initial Penetration Target

Justifying the initial sales volume is the linchpin for the entire 2026 projection of $23 million in revenue. We must map the 450 Pro Systems and 800 Home Systems sales directly to a defintely defined list of target orthopedic groups or hospital systems. The challenge isn't just having FDA clearance; it's proving you can convert a small fraction of available facilities into paying customers quickly. If onboarding takes 14+ days, churn risk rises fast.

Your market penetration rate must be explicitly tied to securing these anchor accounts. For instance, capturing 5% of regional orthopedic centers might justify the 450 Pro System forecast, but you need documented Letters of Intent (LOIs) to back that assumption up. Without this, the unit forecast is just a wish.

Justifying Unit Volume

Here's the quick math on hardware contribution: 450 Pro Systems at $2,450 ASP plus 800 Home Systems at $850 ASP equals about $1.48 million in hardware revenue. This is a small fraction of the total $23 million goal, meaning the bulk of 2026 revenue relies on selling disposable garment packs. You need to show how many disposable units support that initial hardware sale.

Focus sales efforts on securing three major hospital systems willing to commit to minimum quarterly disposable orders to validate the model. The real profitability lever is the recurring revenue from the $45 ASP garment packs, which must be forecast based on expected patient usage days per device sold this year. What this estimate hides is the sales cycle length for capital equipment.

Step 3 : Structure COGS and Supply Chain

COGS and Scale Risk

Documenting your Cost of Goods Sold (COGS) is non-negotiable when manufacturing medical devices. For this business, contract manufacturing costs hit 85% of revenue in 2026, which is extremely high. You must know exactly what drives that percentage down over time. If you don't nail down those unit economics now, profitability projections fall apart fast.

The supply chain must support massive unit growth. You're looking at scaling disposable units from 12,000 units in 2026 to 380,000 units by 2030. That's a huge jump in inventory needs and warehousing demands. Poor logistics here means stockouts or massive carrying costs, defintely killing cash flow.

Locking Down Manufacturing

You need firm contracts with your contract manufacturer based on volume tiers. Negotiate the cost structure for the disposable garments specifically. If you hit 100,000 units annually, what is the new per-unit price? Getting this locked in protects your gross margin as you scale.

Map out the logistics structure for the 380,000 unit volume now. Even if you only ship 12,000 next year, your warehousing and shipping agreements must anticipate that 2030 load. Understand the landed cost per unit, including freight and duties, to ensure the 85% COGS target improves.

Step 4 : Build the Core Team and Salary Model

Team Foundation

Defining your initial 7 FTEs for 2026 sets your immediate fixed cost structure. You must account for key roles like the CEO ($185,000 salary) and the Director of Quality ($145,000 salary) right away. These salaries are non-negotiable starting expenses that must be covered before the projected rapid breakeven in February 2026. You're establishing the leadership needed to manage regulatory adherence and initial market entry.

This small core team needs to be highly effective because cash is tight until revenue stabilizes. Honestly, getting the quality function staffed immediately is critical given you sell FDA-cleared medical devices. If onboarding takes 14+ days, compliance risk rises. This initial group must manage the projected $23 million revenue target for the first year.

Scaling Headcount

The hiring plan must map the growth from 7 people in 2026 to 31 FTEs by 2030. This scale-up needs to heavily favor capacity in sales and engineering to support the projected growth to $488 million in revenue. Sales hires directly attack the market penetration goals for the Pro and Home systems.

To manage this, budget for hiring about 6 new people annually after year one. Remember, the loaded cost-salary plus benefits and taxes-is defintely higher than the base salary figure. Focus hiring on roles that directly support unit volume, specifically those selling the $2,450 VenaFlow Pro System and managing the 380,000 disposable units needed that year.

Step 5 : Calculate Startup Costs and Funding Needs

Initial Spend Reality

You need hard assets before you sell anything. This initial capital expenditure (CapEx) covers the necessary groundwork to start production. We're looking at $375,000 in upfront costs just to build the groundwork. A big chunk of this, $125,000, is dedicated specifically to the manufacturing molds required for the device components. This spending happens before the first dollar of revenue hits the bank.

Peak Cash Burn

The real danger isn't the initial CapEx; it's the cash needed to cover operating losses until you hit breakeven, defintely. We project the minimum cash requirement, or peak cash burn, will hit $805,000. This critical low point occurs in February 2026. That's just two months after you launch, so you must secure funding well before then to survive that initial ramp.

Step 6 : Develop the 5-Year Profit and Loss (P&L) Forecast

Validate Scale Potential

The 5-Year P&L forecast is where assumptions meet reality. It validates if your unit economics can support massive scale. If you project revenue hitting $488 million by 2030 from a $23 million start in 2026, the underlying assumptions about market penetration and pricing must be rock solid. This projection confirms the potential for outsized investor returns, but watch the Cost of Goods Sold (COGS) closely, as high COGS can erode these great numbers fast. Honestly, this step is defintely where you prove the whole model works.

Hit Target Returns

To hit the projected returns, you must drive volume through both device sales and the recurring disposable garment packs. The model shows revenue scaling from $23M in 2026 to $488M in 2030. This aggressive growth path supports an expected Internal Rate of Return (IRR) of 2442% and a massive Return on Equity (ROE) of 7939%. Ensure your supply chain (Step 3) can handle the jump from 12,000 disposables sold in 2026 to 380,000 by 2030; that volume drives the margin needed for these returns.

Step 7 : Determine Breakeven and Profitability Levers

Rapid Profitability Check

Hitting breakeven quickly validates the funding ask and operational assumptions. The plan shows cash neutrality in February 2026, just 2 months post-launch. This rapid timeline relies heavily on achieving the projected 11-month payback period for initial capital. Honestly, the current 110% Cost of Goods Sold (COGS) figure presents a defintely massive, immediate risk to that timeline.

If you don't fix the input cost structure, the projected profitability won't matter. The early breakeven date is aggressive because it assumes you start generating positive cash flow immediately after the $805,000 minimum cash need is met in December 2025. This requires tight control over initial inventory purchases.

Margin Control Focus

You must immediately address the 110% COGS figure noted in the forecast. If COGS exceeds 100% of revenue, you lose money on every unit sold before factoring in any operating expenses. This means your gross margin is negative, which is unsustainable.

The primary lever isn't sales volume, but driving down manufacturing and supply chain costs identified in Step 3. Focus engineering and procurement efforts on reducing the cost per VenaFlow Pro System and Home System unit. That cost reduction is the key to unlocking the high gross margins needed for the 7939% Return on Equity (ROE).